Detalhe da pesquisa
1.
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.
Lancet
; 401(10394): 2138-2147, 2023 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37321235
2.
Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial.
Crit Care
; 24(1): 74, 2020 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32131866
3.
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults.
J Travel Med
; 31(2)2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38091981
4.
Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults.
Lancet Infect Dis
; 23(10): 1186-1196, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37419129
5.
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
J Infect
; 87(3): 242-254, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37406777
6.
A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccine.
J Travel Med
; 2022 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36377643
7.
Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
Lancet Infect Dis
; 22(12): 1716-1727, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36075233
8.
Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.
J Infect
; 85(3): 306-317, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35718205
9.
Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial.
Lancet Infect Dis
; 20(10): 1193-1203, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32497524
10.
Neutralizing antibody persistence in pediatric travelers from non-JE-endemic countries following vaccination with IXIARO® Japanese encephalitis vaccine: An uncontrolled, open-label phase 3 follow-up study.
Travel Med Infect Dis
; 34: 101616, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32156630
11.
Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: A five year follow-up study.
Vaccine
; 37(19): 2529-2531, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30962094
12.
Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose.
Pediatr Infect Dis J
; 37(9): e233-e240, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29912844
13.
Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO®, JESPECT®) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study.
Travel Med Infect Dis
; 22: 18-24, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29549036
14.
Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region.
Pediatr Infect Dis J
; 36(9): 898-904, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28430748
15.
Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children: An Open-label, Randomized, Active-controlled, Phase 3 Study.
Pediatr Infect Dis J
; 36(9): 889-897, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28441266
16.
Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.
Vaccine
; 34(38): 4579-4585, 2016 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-27460550
17.
Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers.
Vaccine
; 34(23): 2585-92, 2016 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27079932